NCT06293118Not yet recruiting
The Effects of Ischemic Conditioning in Individuals With Parkinson's Disease
The Chronic Effect of Ischemic Conditioning on Cognitive Performance, Motor Function and Immune System in Individuals With Parkinson's Disease
Source: ClinicalTrials.gov · Last updated 29 Sept 2026
Brief summary (registry, in English)
Ischemic conditioning (IC) is a promising therapy that can mimic the physiological effects of physical exercise. IC consists of using a cuff to measure blood pressure and calibrate 200 mmHg on the upper or lower limb. Thus, at alternating intervals of 5 minutes, ischemia or reperfusion occurs, depending on whether the cuff is inflated or deflated. IC induces changes in spinal cord excitability for the last reflex reactions of recruited motoneurons with improved balance control in healthy young people and improved learning in the elderly. The objective of the present study is to evaluate the chronic effect of IC on the cognitive performance of patients with Parkinson's disease. Furthermore, the investigators will evaluate secondary outcomes such as the motor function, mobility, quality of life, and immunological responses.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 19 Feb 2024
- Start date
- 1 Oct 2026
- Primary completion date
- 1 Aug 2028
- Lead sponsor
- Hospital Israelita Albert Einstein
- Diseases
- Parkinson disease
- NCT number
- NCT06293118
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 1 Oct 2026 to the primary completion date, 1 Aug 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous deep vein thrombosis;
Other illness
- Patients with uncontrolled diabetes mellitus or peripheral neuropathy;
- Uncontrolled arterial hypertension (BP\>160/100mmHg);
- Pre-existing autoimmune diseases;
- Infectious conditions for less than 1 month;
- History of anemia, cerebral vascular disease, myocardial infarction in the last 6 months;
- Symptomatic peripheral arterial obstructive disease;
Lab values
- Uncontrolled diabetes (Fasting glucose \> 250mg/dl, peripheral retinopathy or diabetic ketoacidosis);
Other
- Uncontrolled dyslipidemia (total chol \> 220mg/dL);
- Neurological problems that prevent training from being carried out;
- Smoking \< 6 months;
- Cognitive dysfunction: Moca \< 24.
Who the study is looking for
- PD patients aged 40 years or older;
- Diagnosis of PD without cognitive complaints or with complaints, but without impact on daily activities;
Age in the registry: 40 years to 90 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.